Research Article| Volume 19, ISSUE 3, P520-526, May 1997

Ceftazidime and ciprofloxacin as empiric therapy in febrile neutropenic patients undergoing hematopoietic stem cell transplantation

      This paper is only available as a PDF. To read, Please Download here.


      This pilot study was done to assess the efficacy and toxicity of intravenous ceftazidime and ciprofloxacin in patients developing febrile neutropenia while undergoing high-dose myeloablative therapy and hematopoietic stem cell transplantation (HSCT). All patients undergoing high-dose chemoradiotherapy and HSCT for leukemias, lymphomas, multiple myeloma, and solid tumors received open-label ceftazidime 2 g intravenously every 8 hours and ciprofloxacin 400 mg intravenously every 12 hours if they developed fever while they were neutropenic. Success with or without modification of this regimen was defined as survival through the neutropenic period; failure was defined as death secondary to infection. Among 45 patients treated with this regimen, the success rate was 98%. Sixty-two percent (28 of 45) of the patients achieved defervescence within 48 to 72 hours and remained afebrile without regimen modification. In 16 patients (36%) the regimen was modified because of persistent fever. The combination of ceftazidime and ciprofloxacin as initial empiric antibacterial therapy in febrile neutropenic patients undergoing myeloablative therapy and HSCT appears to be highly effective and is associated with minimal toxicity.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bodey GP
        • Buckley M
        • Sathe YS
        • Freireich EJ
        Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia.
        Ann Intern Med. 1966; 64: 328-340
        • Hathorn JW
        • Pizzo UA
        Infectious complications in the pediatric cancer patient.
        in: Pizzo PA Poplack DG Principles and Practice of Pediatric Oncology. Lippincott, Philadelphia1989: 837-867
        • Bayston KF
        • Want S
        • Cohen J
        A prospective, randomized comparison of ceftazidime and ciprofloxacin as initial empiric therapy in neutropenic patients with fever.
        Am J Med. 1989; 87 (Suppl 5A): 269-273
        • Klastersky J
        Empiric treatment of infections in neutropenic patients with cancer.
        Rev Infect Dis. 1983; 5: 21-31
        • Lieschke GH
        • Bell D
        • Rawlinson W
        • et al.
        Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: An overview.
        Eur J Cancer Clin Oncol. 1989; 25: 37-42
        • Schimpff S
        • Satterlee W
        • Young V
        • et al.
        Empiric therapy with carbenicillin and gentamycin for febrile patients with cancer and granulocytopenia.
        NEJM. 1971; 28: 1061-1066
        • Freidfeld AG
        • Walsh T
        • Marshall D
        • et al.
        Monotherapy for fever and neutropenia in cancer patients. A randomized comparison of ceftazidime versus imipenem.
        Clin Oncol. 1995; 13: 165-176
        • Hauer C
        • Urban C
        • Slavc I
        • et al.
        Imipenem-cilastatin monotherapy in juvenile cancer patients with neutropenia.
        Pediatr Hematol Oncol. 1990; 7: 229-241
        • Huijgens PC
        • Ossenkoppelle GJ
        • Bostrom M
        • Larsson KJ
        Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: An open study in patients with hematologic malignancies.
        Eur J Haematol. 1991; 46: 42-46
        • Liang R
        • Yung R
        • Chiu E
        • et al.
        Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
        Antimicrob Agents Chemother. 1990; 27: 745-748
        • Pizzo PA
        • Hathorn JW
        • Hiemenz J
        • et al.
        A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.
        NEJM. 1986; 315: 552-558
        • Rolston K
        • Berkey P
        • Bodey G
        • et al.
        A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
        Arch Intern Med. 1992; 152: 283-291
        • Sanders J
        • Powe N
        • Moore R
        Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis.
        J Infect Dis. 1992; 164: 907-916
        • Wade J
        • Standiford H
        • Drusano G
        • et al.
        Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
        Am J Med. 1985; 78 (Suppl 5A): 62-72
        • Fink MP
        • Snydman DR
        Treatment of severe pneumonia in hospitalized patients: Results of a multi-center, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin Niederman MS.
        Antimicrob Agents Chemother. 1994; 38: 547-557
        • Chan CC
        • Oppenheim BA
        • Anderson H
        • et al.
        Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.
        Antimicrob Agents Chemother. 1989; 33: 87-91
        • Kelsey SM
        • Collins PW
        • Delord C
        • et al.
        A randomized study of teicoplanin plus ciprofloxacin versus gentamycin plus piperacillin for the empirical treatment of fever in neutropenic patients.
        Br J Haematol. 1990; 76: 10-13
        • Malik I
        • Khan WA
        • Karim M
        • et al.
        Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial.
        Am J Med. 1995; 98: 224-231
        • Malik I
        • Khan W
        • Aziz A
        • Karim M
        Self-administered antibiotic therapy for chemotherapy-induced low-risk febrile neutropenia in patients with non-hematologic neoplasms.
        Clin Infect Dis. 1994; 19: 522-527
        • EORTC International Antimicrobial Therapy Cooperative Group
        Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram negative bacteremia in cancer patients with granulocytopenia.
        NEJM. 1987; 317: 1697-1698